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Summary: In the course of chronic inflammatory and degenerative joint diseases proteoglycans are degraded by
the action of proteases and oxygen radicals. Therefore, proteoglycan fragments, released from cartilage into the
peripheral blood, might be useful markers of cartilage degradation. Sensitive enzyme immunoassays are useful for
the detection of these proteoglycan fragments in serum. We therefore developed specific monoclonal antibodies
against the large aggregating proteoglycan (aggrecan), which has been isolated and purified from human articular
cartilage. Tsvo monoclonal antibodies which recognize a novel cartilage-specific epitope on the keratan sulphate
chain of aggrecan (mAb 4B3/D10) and an epitope of the core-protein of aggrecan (4G4/A10) were selected for the
development of competitive enzyme-immunoassays. These assays allow the sensitive and specific detection of
cartilage-derived proteoglycan fragments, not only in synovial fluid but also in serum. They can now be used for
the study of inflammatory and degenerative joint diseases.
Introduction patients with different joint diseases (1—7). However,
. . _ , . . rt , , . theuseof these monoclonal antibodies, which recognizeIn the course of chromc inflammatory and degenerative . . . ,. . , 4 , . r^ , , ,. . , . f j j j · i · an epitope in the disulphated region of the keratan sul-jomt diseases, proteoglycans are degraded by the action . . .
-, „ f · t_ i j · t u · * Phate chain (8)> has provided no clear correlation be-of proteases which are released either by inflammatory r , , , , , ·, < » * -i
n , , , , , tween keratan sulphate levels and the degree of cartilagecells, e. g. granulocytes and monocytes, or by chondro- : ' . . °
^ , ,u i -m. ^ . 4, degradation or disease activity (1—7). A major reasoncytes themselves. Therefore, proteoglycan fragments re- . , , , , .t . .^ ~
leased from the cartilage may be useful markers of carti- mlSht be that these anfbodies are not spec.fic for aggre-
läge degradation. During the past few years several can from artlcular cartllaSe' but also react Wlth keratan
groups have tried to use monoclonal antibodies specific sulPhate from other sources' e'S- intervertebral disc,
for keratan sulphate chains of the large aggregating pro- comea or blood vessels (9~] ̂  ̂ ese data clearly dem-
teoglycan (aggrecan), a major component of the extra- onstrate that monitoring of cartilage damage will require
cellular rnatrix of cartilage, for the determination of to- monoclonal antibodies with much higher specificity for
ratan sulphate levels in serum and synovial fluid of cartilage than those used Previously. Therefore we de-
cided to generate novel monoclonal antibodies against
_ different cartilage-specific epitopes of the large aggre-
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Scphadcx G-25, Sepharose Q, Protein-G-Sepharose, the TSK G
4000 SW column (7.5 mm X 300 mm), the TSK G SWP guard-
colunin (7.5 mm X 75 mm) and preformed gels for SDS-polyacryl-
amidc-gcl elcctrophoresis (4-15% gradient) werc obtained from
Pharmacia/LKB (Frciburg, Gcrmany). Hydroxyapatite and Zcta-
Probe blotling membrane wcre obtained from Bio-Rad (Munich,
Germany). Polyvinylidcnefluoride blolting membranes (Fluoro-
trans) werc purchased from Pal l (Dreieich, Germany). High molec-
ular mass Standards, 3-[3-cholamido-propyl)-dimethylamino]-l-
propane-sulphonate (CHAPS), benzamidine hydrochloride, 6-ami-
nohexanoic acid, phenylmcthylsulphonyl fluoride and N-ethylma-
leinimide were purchased from Sigma (Deisenhofen, Germany).
Diaminobenzamidine-tetrahydrochloride was from Serva (Heidel-
berg, Gcrmany), o-phenylencdiamine (OPD, 2 mg tablets) and rab-
bit-anli-mouse-Ig-antiscrum were from DAKO (Kopenhagen,
Denmark). Peroxidase-conjugated streptavidin and peroxidase-con-
jugated goat-antibodies againsl mouse-IgG were from Dianova
(Hamburg, Gcrmany). Chondroilin sulphate lyase AC (EC
4.2.2.5)2), chondroitin sulphate lyase ABC (EC 4.2.2.4), keratan
sulphate hydrolyase (EC 3.2.1.103), keralan sulphate endo-ß-N-
acetyl-glucosaminidase (keratanase II) and the keratan sulphate-
specific monoclonal antibody mAB 5D4 were obtained from Seika-
gaku (Tokio, Japan). Sulphosuccinimidyl-6-(biotinamido)-hexano-
ate (NHS-LC-biotin) was from Pierce (Munich, Germany). Poly-
cthylene glycol 1500 (PEG 1500) and trypsin (EC 3.4.21.4) was
from Boehringer Mannheim (Mannheim, Germany). All othcr re-
agcnts werc of analytical grade (Merck, Darmstadt, Germany).
Mclhods
Isolation and purificafion of the large aggregating proteoglycan
front human arlicular cartilagc
Isolation and purification of the large aggregating proteoglycan
(aggrecan) from human articular cartilage was carried out äs de-
scribed (12—15) and is schematically shown in figure 1. Cartilage
from the fcmur condylcs of 14 donors was pooled; the age of the
donors was in the ränge of 10 lo 82 years. Briefly, proteoglycans
werc cxtracted from cartilage by 4 mol/1 guanidine hydrochloride,
0.05 mol/1 sodium acetate, (pH 5.8) containing 5 g/l CHAPS and
the protease inhibitors benzamidine hydrochloride (0.005 mol/1),
6-aminohexanoic acid (0.1 mol/1), phenylmethylsulphonyl fluoride
(0.005 mol/1), N-ethylmaleimide (0.01 mol/1), and EDTA (0.05
mol/1). The 4 mol/1 guanidine hydrochloride extract of cartilage
was equilibrated with 0.05 mol/1 Tris, 0.05 mol/1 sodium acetate
buffer (pH 5.8) containing 7 mol/1 urea, 0.05 mol/1 NaCl, 0.05
mol/1 LiCl, 2 g/l CHAPS and proteasc-inhibitors (0,001 mol/1 N-
cthylmaleimide, 0.002 mol/1 benzamidine hydrochloride and 0.001
mol/1 phenylmethylsulphonyl fluoride) by size-exclusion chroma-
tography on Sephadex G-25. Aggrecan was isolated by anion-ex-
changc chromatography on Scpharosc Q (Pharmacia/LKB, Frei-
burg, Germany) and further purified by hydroxyapatite chromato-
graphy.
2) Enzymes
Chondroitinasc AC (chondroilin sulphate lyase AC, EC 4.2.2.5)
Chondroitinase ABC (chondroitin sulphate lyase ABC, EC 4,2.2.4)
Keratanase (keralan sulphate hydrolyase, EC 3.2.1.103)
Keratanase 11 (keratan sulphate endo-ß-N-acetylglucosaminidase)
Trypsin (EC 3.4.21.4)
Characterizuiion of the large aggregaüng proteoglycan from hu-
man articular cartilage
For amino acid and amino sugar analysis, an aggrecan sample was
treated with 3 mol/1 HC1 at 105 °C for 15h. Analysis was per-
formed on a LKB-Alphaplus amino acid analyser (Pharmacia/LKB,
Freiburg, Germany).
The prepared aggrecan was showri to be homogeneous by size-
exclusion chromatography on TSK 4000, and was identtöed by
SDS-PAGE and western blot analysis of a native and enzymatically
digested biotinylated sample (16),
Enzymatic and chemical deglycosylation
Enzymatic digestion with chondroitin sulphate lyase AC (EC
4.2.2.5), chondroitin sulphate lyase ABC (EC 4.2.2.4), keratan sul-
phate hydrolyase (EC 3.2.1.103) and keratanase II was performed
in the presence of proteinase inhibitors äs described by Oike et al.
(17). For chemical deglycosylation a lyophilizied aggrecan sample
was treated with trifluormethanesulphonic acid in anisole (18, 19).
Monoclonal antibodies
Monoclonal antibodies were raised in mice according to a modified
protocol of the basic outline of Köhler & Milstein (20). Briefly:
100 g of aggrecan in a volume of 300 ! were mixed with an
equal volume ofFreund's complete adjuvant and injected intraperi-
toneally and subcutaneously into 8 week-old B ALB/c female mice.
The mice received booster injections after 6 weeks in Freund1*
incomplete adjuvant and a final injection 3 days before the fusion.
Serum titres of preimmune and immune sera were determined by
the use of a slot blot enzyme-immuno assay (see below). Spleen
cells of the rnouse with the highest serum titre were fused with the
BALB/c myeloma X63-Ag8/653, using polyethylene glycol. Ceils
were plated in 96-well plates in Dulbecco's minimal essential me-
dium containing foetal calf serum (volume fraction 0.1) and hypo-
xanthine-aminopterine-thymidine. Hybridoma supernatants were
tested by ELISA (see below). Hybridomas that showed a positive
reaction were cloned and subcloned by limiting dilution.
Screening and characterization of monoclonal antibodies
Supernatants were tested for specific antibody against aggrecan by
the use of a slot blot enzyme immuno assay on a zeta probe mem-
brane (Bio-Rad, Munich, Germany). Briefly: 50 ng of the aggreean
preparation were incubated per slot for 10 min at room temperature
on a zeta probe membrane. After blocking of the membrane with
blotto (20 g/l dry milk powder in phosphate buffered saline) for
2 h, 200 of hybridoma supernatants were incubated for 4 h at
room temperature. Bound antibodies were detected by a peroxi-
dase-conjugatcd second antibody firorn goat, üsing diaminobenzid-
ine/H2O2 äs Substrate. Subclass determination of tbe specific mono-
clonal antibodies was done by an ELISA, using subclass specific
antisera (Dianova, Hamburg, Germany). Monoclonal antibodies
from cell culture supernatants were purified by protein G affinity
chromatography according to the manufacturer's instruotions
(Pharmacia Fine Chemicals, Uppsala, Sweden).
Immunochemical characterization off he large aggregating proteo-
glycan
For immunoblots, aggrecan was treated either with chondroitin sul-
phate lyases AC/ABC, with keratan sulphate hydrolyases or with
a combination of these enzymes, then subrnitted to SDS-PAGE on
preformed 4-15% gradient gels (Pharmacia Phast System, Pharm-
acia/LKB). Subsequently they were blotted to polyvinylidenefluor-
ide-membranes (Fluorotrans, Pall) by difftision (16). The mem-
brane was blocked by blotto (20 g/l dry milk powder in tris buff-
ered saline, l h, room temperature) before incubation with mono-
clonal antibody (diluted appropriatQly in blocking solution) for 4 h.
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Bound antibodies wcre detectcd by a peroxidasc-conjugated second
antibody from goat and visualized by the use of 0.05 mol/1 Tris-
HC1, pH 7.4, containing 1.26 mmol/1 3,3'-diaminobenzidine tetra-
hydrochloride and 50 mg/1 H2O2.
Antigen-hihibition-enzyme-immunoassay
Antibodies, specific for keratan sulphate (4B3/D10) or the aggre-
can-core-protein (4G4/A10) were selected for the development of
sensitive antigen-inhibition ELISAs, For dctermination of keratan
sulphate the keratan sulphate-rich region of the large aggregating
protcoglycan (aggrecan) was prepared. Briefly, aggrecan was di-
gested wilh chondroitinase AC/ABC, purificd by gcl-permeation-
chromalography and subsequently digested with trypsin. The kera-
tan sulphate-rich region was isolated and purified by ion-cxchange
chromatography. For determination of Standard Inhibition curves,
variable amounts of the unlabclled and a constant amount of the
biotin-labellcd keratan sulphate-rich region were uscd. For determi-
nation of the aggrecan-core-protein content, the puriiied aggrecan
was used s a Standard. Microtitre-plates (96-well, high protein-
binding capacity, Greiner, N rtingen, Germany) were coated over-
night wilh 100 μΐ per well of a rabbit-anti-mouse antiserum
(DAKO, Kopenhagen, Denmark) diluted l : 1000 in 0.05 mol/1
Na2CO3/NaHCO3 buffcr (pH 9.6), containing 200 mg/1 NaN3.
Thereafter, diluted antiserum was removed, and non-specific bind-
ing sites wcrc blocked by a solution of 20 g/l bovinc serum albu-
min (Behring, Marburg, Germany) in phosphate buffcred saline
(200 μΐ per well, 90 min). All incubations were carried out at 37 °C
in a humidified atmosphere. Specific antibodies (100 μΐ per well),
diluted appropriately in blocking solution, were allowed to bind
for 90 min. To remove unbound antibody, wells were washed three
times (200 μΐ per well of 0.1 mol/1 ΚΗ2Ρθ4/Κ2ΗΡθ4 buffer, pH
6.5). A solution (100 μΐ) containing a mixture of biotin-labellcd
and unlabellcd antigen (see below) was then added. To remove
unbound antigen, wells were washed three times with 200 μΐ of
0.1 mol/1 KH2PO4/K2HPO4 (pH 6.5). Thereafter peroxidase-conju-
gated streptavidin (Dianova, Hamburg, Germany), diluted in 0.2
mol/1 KH2PO4/K2HPO4 buffer (pH 6.5), containing fetal calf serum
(volume fraction 0.2) was added (100 μΐ per well, 45 min). Un-
bound streptavidin was removed by washing the plate 5 times (200
μΐ per well) with 0.1 mol/1 sodiurn citrate/citric acid (pH 5.0). Sub-
strate solution (100 μΐ) was added to the wells (8 mg o-phenylene-
diamine dissolved in 12ml 0.1 mol/1 citrate/citric acid pH 5.0 and
5 μΐ Η2Ο2 (300 g/kg). Colour development was stopped by addition
of 0.5 mol/1 H2SO4 (100 μΐ per well), The plates were read using
an ELISA plate reader (SLT, Overrath, Germany) at a wavelength
of 492 nm; absorbance at 690 nm was used for back-ground sub-
traction.
Antigen
To measure either the keratan sulphate content or the amount of
aggrecan-core-protein present in the sample, Standard-Inhibition
curves (constant amount of biotin-labelled antigen and increasing
amounts of unlabelled antigen) were also determined on each plate.
For measurement of keratan sulphate in the presence of serum,
samples were diluted in a buffer consisting of 20 m*mol/l NaH2PO4;
50 mmol/1 Na2EDTA (pH 4.5) with 10 g/l bovine serum albumin
and 100 μΐ/ΐ Tween-20 prior to adding the biotin-labelled antigen
(2). For determination of core-protein levels in the presence of
serum, the samples were diluted in 10 g/l bovine serum albumin
in phosphate buffered saline, containing l nil/1 Tween-20 prior to
adding the biotin-labelled antigen. Usually, sera were diluted l : 5,
l : 10 and l : 20 in the appropriate buffcr. In both cases, sera,
which had been depleted of either keratan sulphate or aggrecan-
core-protein, wcre uscd for determination of standard-inhibition
curves (see below). The keratan sulphate content of Standard and
sample is expressed s the glucosamine-contenl (nmol/1), and the
amount of aggrecan-core-protein is expressed s the glycine-con-
tent (nmol/1).
Removal of keratan sulphate and aggrecan core-prolein from
serum
Sera used for determination of the Standard Inhibition curves were
submitted to immunosorption by either the keratan sulphate-
specific or the aggrecan-core-protcin specific antibody. Briefly, a
polystyrene tube was coated overnight wilh a rabbit-anti-mousc-
immunogl bulin antiserum (DAKO, Kopenhagen, Denmark) di-
luted l : 1000 in 0.05 mol/1 Na2C03/NaHCO3 buffcr (pH 9.6) con-
taining 200 mg/1 NaN3. Thereafter, antiserum was removed, and
non-specific binding sites were blocked (2 h, 20 g/l bovine serum
albumin in phosphate buffered saline) prior to adding the specific
antibody diluled approprialely in the blocking solution (2 h). Un-
bound antibody was removed by washing the tube three times with
0.1 mol/1 KH2PO4/K2HPO4 (pH 6.5) before addilion of the serum
to be depleted of keratan sulphate and EDTA (final conccntration
50 mmol/1). Keralan sulphate or aggrecan-core-protein were al-
lowed lo bind to the antibody for 8 h or overnight. Depletion of
the antibody-treatcd serum was checked by slot blot enzyme im-
muno assay. Deplcled sera wcre aliquoted and storcd at -20 °C.
Results and Discussion
Isolation and b iochemica l character izat ion of
aggrecan
Aggrecan was isolated from human articular cartilage
and purified by several Chromatographie Steps (fig. 1).
Fractions eluting between 0.9 mol/1 NaCl and 1.9 mol/1
NaCl from the Sepharose Q column were pooled and
submitted to hydroxyapatite chromatography. The
sample eluting between 0.13 mol/1 and 0.17 mol/1
NaH2PO4 from the hydroxyapatite column was submit-
ted to size-exclusion chromatography on TSK 4000. It
revealed a single sharp peak in the void volume of the
Human articular cartilage
Extraction with 4 rnol/l guanidine-HCl in the prescnce
of protease inhibitors
i
Buffer exchange to 7 mol/1 urea
Chromatography on Sephadex G-25
ι
Anion-exchange-chromatography on Sepharose Q FF
linear NaCl-gradient (0.05-4 mol/1 NaCl)
l
Aggrecan containing fractions eluted between








Fig. l Isolation and purification of the large aggregating proteo-
glycan (aggrecan) from human articular cartilage,
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Fig. 2 Gel-permeation chromatography of aggrecan on TSK G
4000 SW. Purified aggrecan was submitted to analytical size ex-
clusion chromatography on a TSK G 4000 SW column (7.5 mm
X 300 mm; precolumn TSK G SWP 7.5 mm X 75 mm), equilib-
rated with a 0.02 mol/1 sodium phosphate buffer (pH 6.0) contain^-
ing 0.3 mol/1 NaCl and 100 mg/1 CHAPS. The sample was applied
to the column and eluted at a flow rate of 0.8 ml/min. Absorbance
was monitored at 210 nm (-
indicated by arrows.
-) and 280 nm (--), V0 and Vt are
column (fig. 2), indicating homogeneity of the isolated
aggrecan. The identity of aggrecan was shown by enzy-
matic digestion with chondroitin sulphate lyases AC/
ABC and keratan sulphate hydrolyases. The core-protein
of aggrecan was labelled with biotin prior to digestion of
the glycosaminoglycan chains* rDigested and ündigested
samples were submitted to SDS-PAGE (4-15% gradi-
ent) and diffusion blot onto nylon membrane. Biotin»
labelled compounds were detected with avidin-peroxi-
dase with diaminobenzidine äs Substrate. After digestion
of aggrecan with a combination of the chondroitin sul-
phate lyases AC/ABC and keratanases, a band corre-
sponding to Mr of about 200 000, i. e. the size of aggre-
can-core-protein was detected (fig. 3); the band above
MT 200 000 is most likely due tp ineomplete remqval of
the glycosaminoglycan-side chains. The same holds true
for the additional band seen in figure 4c. No other bänds,
indicating the presence of smaller proteoglycans, could
be detected. The amino acid and hexösamine compo-
sition of aggrecan is given in table 1.
Preparation and characterization of
monoclonal antibodies
The aggrecan preparation was used for immunization of
mice. A series of more than 20 monoclonal antibodies
was obtained. Two of these monoclonal antibodies were
selected for further characterization and subsequently







Fig. 3 Diffusion blot of native and enzymatically digested biotin-
ylated large aggregating proteoglycan. Biotinylated large aggregat-
ing proteoglyean from human articular cartilage was submitted to
SDS-PAGE on a 4-15% gradient gel and blotted onto nitrocellu-
lose membrane.
1. native biotinylated sample; 2. sample after chondroitinase AC/0
ABC treatment; 3. sample after keratanase treatment; 4. sample°
after treatment with condroitinase AC/ABC and keratanase.
Tab. l Amino acid- and hexosarnine-content of the purified large
aggregating proteoglycan frorh human artieulär cartilage.
Amino acid contents are expressed in mol/1000 mol; the rhplar
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Fig. 4 Immunochemical characterization of the large aggregating
proteoglycan from human articular cartilage. Diffusion blot of
native large aggregating proteoglycan from human articular carti-
lage (Panel A and B, lane l and 4), and the same material after
digestion with chondroitinase AC/ABC (Panel A and B, lane 2),
keratanase (Panel A and B, lane 3), or chondroitinase AC/ABC
and keratanase (Panel A and B, lane 5). Proteoglycans were sub-
mitted to SDS-PAGE on a 4-15% gradient gel and subsequently





detection was performed with either the keratan sulphate-specific
monoclonal antibody 4B3/D10 (Panel A) or 5D4 (Panel B). For
immunochemical detection of the core-protein, aggrecan, digested
with chondroitinase AC/ABC and keratanase (Panel C, lane 1), äs
wel] äs native aggrecan (Panel C, lane 2) was submitted to SDS-
PAGE on a 4-15% gradient gel and subsequently blotted onto
polyvinylidene-fluoride-membrane. Immunochemical detection
was perfbrmed with the core-protein-specific monoclonal antibody
4G4/A10.
determine the specificity of these antibodies, native and
enzymatic or chemically deglycosylated aggrecan was
submitted to SDS-PAGE and Western-blot. The epitope,
recognized by the monoclonal antibody mAb 4B3/D10
is completely removed by keratanase digestion (fig. 4a),
indicating that this antibody ireacts with keratan sulphate
chains present on aggrecan. In this respect the antibody
seems to be similar to the pfeviously described keratan
sulphate-specific monoclonal antibody mAb 5D4 (fig.
4b) (1). This monoclonal antibody, and several others
with the same specificity, which have been described in
the meantime (2, 21), were shown to recognize a highly
sulphated epitope present at the non-^reducing end of
keratan sulphate chains (8, 21-=23). Since this epitope
is a common feature of keratan sulphate chains, these
antibodies reäct equally well with keratan sulphate iso-
lated from different tissües and species (9^-11, 24, 25).
In contrast, the monoclonal antibody mAb 4B3/D10
shows high specificity for the keratan sulphate chains
present on aggrecan from human artieular cartilage, but
little or no reactivily with kei;atan sulphate isölated from
human intervertebral disc (manuscript in preparation).
These fmdings indicate that the monoclonal antibody
mAb 4B3/D10 recogiiizes a novel epitope on the keratan
sulphate chain, which is preferentially expressed on the
large aggregating proteoglycan in cartilage. ta contrast,
reactivity of aggrecan with the monoclonal antibody
mAb 4G4/A10 is neither influenced by enzymatic nor
by chemical deglycosylation of aggrecan (fig. 4c), indi-
cating that this antibody recognizes an epitope present
on the core-protein of aggrecan.
Development of enzyme immunoassays
specific for keratan sulphate- and core-
protein-epitopes of the large aggregating
proteoglycan from human articular cartilage
In the course of chronic inflammatory and degenerative
joint diseases cartilage is degraded by the action of pro-
teases and oxygen radicals. Thefefore, proteoglycan
fragments, released from the cartilage into the peripheral
blood, may be useful markers of cartilage degradation.
So far> only monoclonal antibodies with a specificity
similar to the monoclonal antibody mAb 5D4 have been
used for the measurement of keratan sulphate in serum
of patients with different joint diseases (3—7). However,
using these antibodies, only a poor correlation between
disease activity, cartilage destruction and the keratan
sulphate levels in the serum was obtained. In contrast to
these results, analysis of keratan sulphate levels in syn-
ovial fluid gave rather promising results. This might be
explained by the lack of cartilage specificity of the anti-
bodies used. Even though little is known about the
metabolism of keratan sulphate, it is clear that keratan
sulphate is released into the serum not only from carti-
lage, but also from intervertebral disc, the blood vessels
and perhaps other Organs (6, 9-11, 24-25). Therefore,
when using antibodies which do not discriminate be-
tween keratan sulphate from these different sources,
analysis of keratan sulphate levels in serum might be
influenced strongly by keratan sulphate from other
sourees than cartilage. In contrast, analysis of keratan
sulphate in synovial fluid, which is released mainly from
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cartilage, is affected only slightly by keratan sulphate
from other origins.
Therefore, the use of monoclonal antibodies with high
specificity for epitopes expressed exclusively or at least
preferentially on keratan sulphate chains of the large ag-
gregating proteoglycan from articular cartilage seems to
be necessary for a specific measurement of keratan sul-
phate release from cartilage into the serum. Moreover,
the determination of a pattern of cartilage-specific prote-
oglycan-epitopes, present in the serum, might give a bet-
ter correlation between cartilage destructioü and disease
activity than the determination based on only one epi-
tope. We therefore made novel monoclonal antibodies
with higher specificity for cartilage-specific epitopes of
the large aggregating proteoglycan.
As little is known about the size and the composition of
proteoglycan fragments released from cartilage (26, 27)
we decided to use these antibodies for the development
of a sensitive antigen-inhibition-assay. This type of as-
say does tiot depend on repetitive epitopes, or on the
expression of two defined different epitopes on one frag-
ment, a prerequisite for classical Sandwich immuno as-
says. In this type of antigen-inhibition assay a constant
amount of biotin-labelled antigen is added to the sample,
and competes with the unlabelled antigen present in the
sample for binding to the immobilized antibody. Biotin-
labelled antigen, bound to the antibody, is detected by
the use of streptavidin-peroxidase and o-phenylene di-
amine äs Substrate. An example of the standard-inhi-
bition curves for both assays described is shown in fig-
ure5.
One major point, which has not been adressed properly
in previous work, is the interaction of keratan sulphate
with serum components. In fact, strong interactions be-
tween serum and keratan sulphate have been observed.
This has been successfully overcome by the use of either
50 mmol/1 EDTA and 100 / Tween-20 (4B3/D10) or
50 mmol/1 EDTA and l ml/l Tween-20 (5D4) in the
sample buffer. The observation that Tween-20 and
EDTA are required for counteracting the interaction be-
tween keratan sulphate and serum points to a Ca2+-de-
pendent interaction. In the case of the core-protein-
specific antibody, there is virtually no interaction be-
tween the matrix and the large proteoglycan added. The
keratan sulphate content of the Standard is expressed äs
the molar amount of glucosamine rather than äs g/l of
keratan sulphate; the core-protein-content of the Stan-
dard is expressed äs the molar amount of glycine. In
our opinion, expressing the keratan sulphate-content äs
glucosamine-content reflects more closely the real kera-
tan sulphate-content, since the keratan sulphate-specific
antibodies recognize epitopes containing at least one °







Fig. 5 Standard inhibitipn-curves obtained with the monoclonal
antibody 4G4/A10. Increasing amounts of aggrecan (40 nmol/1 to
1060 nmol/1, expressed äs glycine content) were added to serum
which had been depleted of core-protein. A constant amount of
biotin-labelled aggrecan (112 nmol/1, expressed äs glycine-content)
was added and the sera were allowed to bind to the immobilized
antibodies. Bound, biotin-labelled antigen was detected with per-
oxidase-conjugated streptavidin äs described under Material and
Methods.
—O— Standard Inhibition curve obtained in the presence of 20 g/l
bovine serum albumin
-O- Standard Inhibition curve obtained in the presence of core-
protein-depleted serum
considering the specificity of the assay is the source of
antigen used, because different binding affinities for
antigens will greatly influence the outcome of the assay
(6, 10). In our opinion it is absolutely necessary to use
aggrecan from human articular cartilage äs competing
labelled antigen in this type of assay.
The reliability of these assays was analysed with respect
to sensitivity and precision. For the within-run- and be-
tween-rtm imprecision coefficieüt of Variation (GV) va-
lues of < 10% were obtained. The CV values were de-
termined for keratan sulphate concentrations of 1790
nmol/1 (l : 5 diluted serum, n = 10, CV = 7.7%) and
core-protein concentrations of 66 nmol/1 (1:5 dilüted
serum, n = 10, CV = 9.9%). Under the conditipns de-
scribed the lower detection limit of the assays was about
10 nmol/1 glycine (4G4/A10) and 20 nmol/1 glucos-
amine (5D4, 4B3/D10) respectively.
The assays described in the present report allow the sen-
sitive determination of cartilage-specific keratan sul-
phate and aggrecan core protein levels in human sera
and will now be used for the study of different inflam-
matory and degenerative joint (Jiseases. A major advan-
tage of these novel assays lie^ in their higher cartilage
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specificity, which will allow the sensitive and specific
detection of cartilage damage not only in synovial fluid
samples (3) but also in serum samples, an essential pre-
requisite for a broad application of these assays. The
assays will be useful in the analysis of cartilage metab-
olism and breakdown in joint diseases, in monitoring
.disease progression, but also in the search for improved
drugs. They might contribute also to an understanding
of the relation of inflammation and destruction in joint
diseases.
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